COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August-October 2020.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
13 03 2021
Historique:
received: 11 02 2021
revised: 09 03 2021
accepted: 11 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 23 4 2021
Statut: epublish

Résumé

COVID-19 pandemic is a dramatic health, social and economic global challenge. There is urgent need to maximize testing capacity. Rapid Antigen Tests (RAT) represent good candidates for point-of-care and mass surveillance testing to rapidly identify SARS-CoV-2-infected people, counterbalancing lower sensitivity vs. gold standard molecular tests with fast results and possible recurrent testing. We describe the results obtained with the testing algorithm implemented at points of entry (airports and ports) in the Lazio Region (Italy), using the STANDARD F COVID-19 Antigen Fluorescence ImmunoAssay (FIA), followed by molecular confirmation of FIA-positive samples. From mid-August to mid-October 2020, 73,643 RAT were reported to the Regional Surveillance Information System for travelers at points of entry in Lazio Region. Of these, 1176 (1.6%) were FIA-positive, and the proportion of RT-PCR-confirmed samples was 40.5%. Our data show that the probability of confirmation was directly dependent from the semi-quantitative FIA results. In addition, the molecularly confirmed samples were those with high levels of virus and that were actually harboring infectious virus. These results support public health strategies based on early mass screening campaigns by RAT in settings where molecular testing is not feasible or easily accessible, such as points of entry. This approach would contribute to promptly controlling viral spread through travel, which is now of particular concern due to the spread of SARS-CoV-2 variants.

Identifiants

pubmed: 33805832
pii: biom11030425
doi: 10.3390/biom11030425
pmc: PMC7999510
pii:
doi:

Substances chimiques

Antigens, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero della Salute
ID : Ricerca Corrente - linea 1
Organisme : Ministero della Salute
ID : COVID-2020-12371817
Organisme : European Commission
ID : 101003544 - CoNVat
Organisme : European Commission
ID : 101005111-DECISION
Organisme : European Commission
ID : 101005075-KRONO
Organisme : European Commission
ID : European Virus Archive - GLOBAL (grants no. 653316 and no. 871029)
Organisme : Regione Lazio
ID : Health Authority

Références

Euro Surveill. 2020 Apr;25(14):
pubmed: 32290902
J Clin Virol. 2020 Nov;132:104654
pubmed: 33053494
Biochem Biophys Res Commun. 2021 Jan 29;538:226-230
pubmed: 33139015
Nat Rev Microbiol. 2021 Mar;19(3):171-183
pubmed: 33057203
Clin Microbiol Infect. 2021 Mar;27(3):487-488
pubmed: 32979567
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32843531
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
Open Forum Infect Dis. 2020 Sep 02;7(10):ofaa403
pubmed: 33527081
Int J Infect Dis. 2021 Mar;104:282-286
pubmed: 33130198
Int J Infect Dis. 2020 Oct;99:328-333
pubmed: 32497809
JAMA. 2020 Nov 10;324(18):1813-1815
pubmed: 33084882
J Clin Virol. 2020 Aug;129:104500
pubmed: 32585619

Auteurs

Francesca Colavita (F)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Francesco Vairo (F)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Silvia Meschi (S)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Maria Beatrice Valli (MB)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Eleonora Lalle (E)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Concetta Castilletti (C)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Danilo Fusco (D)

Lazio Regional Health Service, 00145 Rome, Italy.

Giuseppe Spiga (G)

Lazio Regional Health Service, 00145 Rome, Italy.

Pierluigi Bartoletti (P)

Regional Special Unit for Community Health Care (USCAR), National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Simona Ursino (S)

Local Health Authority-Roma 4, Civitavecchia, 00153 Rome, Italy.

Maurizio Sanguinetti (M)

Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.

Antonino Di Caro (A)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Francesco Vaia (F)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Giuseppe Ippolito (G)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Maria Rosaria Capobianchi (MR)

National Institute for Infectious Diseases, "Lazzaro Spallanzani" IRCCS, 00149 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH